Fmr LLC Olema Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 1,036 shares of OLMA stock, worth $14,089. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,036

Previous 996 4.02%

Holding current value

$14,089

Previous $11,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$8.73 - $13.99 $349 - $559	40 Added 4.02%	1,036 $11,000
Q1 2024 May 13, 2024	BUY	$10.95 - $16.62 $963 - $1,462	88 Added 9.69%	996 $11,000
Q4 2023 Feb 13, 2024	SELL	$10.53 - $17.14 $7,665 - $12,477	-728 Reduced 44.5%	908 $12,000
Q3 2023 Nov 13, 2023	BUY	$8.19 - $12.98 $7,960 - $12,616	972 Added 146.39%	1,636 $20,000
Q2 2023 Aug 11, 2023	SELL	$3.22 - $9.65 $25 - $77	-8 Reduced 1.19%	664 $5,000
Q1 2023 May 11, 2023	SELL	$2.55 - $4.97 $61 - $119	-24 Reduced 3.45%	672 $2,000
Q4 2022 Feb 13, 2023	BUY	$2.27 - $3.76 $776 - $1,285	342 Added 96.61%	696 $1,000
Q3 2022 Nov 10, 2022	SELL	$2.72 - $5.88 $9,734 - $21,044	-3,579 Reduced 91.0%	354 $1,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.61 $213,612 - $482,722	-104,712 Reduced 96.38%	3,933 $16,000
Q1 2022 May 13, 2022	SELL	$3.89 - $9.43 $1.77 Million - $4.28 Million	-454,209 Reduced 80.7%	108,645 $463,000
Q4 2021 Feb 14, 2022	SELL	$8.75 - $30.71 $386,723 - $1.36 Million	-44,197 Reduced 7.28%	562,854 $5.27 Million
Q3 2021 Nov 15, 2021	SELL	$22.96 - $30.13 $819,672 - $1.08 Million	-35,700 Reduced 5.55%	607,051 $16.7 Million
Q2 2021 Aug 13, 2021	BUY	$21.15 - $36.14 $13.6 Million - $23.2 Million	642,751 New	642,751 $18 Million

Others Institutions Holding OLMA

# of Institutions

129

Shares Held

57.8M

Call Options Held

57.5K

Put Options Held

34K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $550M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account